摘要
急性心力衰竭(AHF)是以心输出量降低、组织灌注减少及肺毛细血管楔压升高为特征的临床综合征。利尿剂为体液容量超载心力衰竭患者的首选治疗药物。AHF不伴低血压患者的一线治疗药物为血管扩张剂。上述干预未奏效的组织低灌注者,可按病情选用正性肌力药物治疗。本文简要介绍AHF的药物治疗及心脏肌球蛋白激活剂、istaroxine、利钠肽、腺苷受体拮抗剂以及血管加压素受体拮抗剂等新药的研究进展。
Acute heart failure （AHF） is a clinical syndrome characterized by cardiac output reducing, hypoperfusion and pulmonary capillary wedge pressure increasing. Diuretics are the primary drug treatment for volume overload in patients with heart failure. In the absence of hypotension, vasodilators are recommended for most patients with AHF as first line therapy. Positive inotropic agents are reserved for use in selected situations of hypoperfusion when other interventions are inappropriate or have failed. Potential future therapies, including cardiac myosin activators, istaroxine, natriuretic peptide, adenosine antagonists and vasopressin antagonists are described briefly.
出处
《世界临床药物》
CAS
2009年第1期46-51,共6页
World Clinical Drug
